Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
APVO Stock Chart & Stats
$0.61
-$0.30(-5.81%)
At close: 4:00 PM EST
$0.61
-$0.30(-5.81%)
Day’s Range― - ―
52-Week Range$3.95 - $1,299.60
Previous CloseN/A
Volume25.11K
Average Volume (3M)11.64M
Market Cap
$4.50M
Enterprise Value-$9.97M
Total Cash (Recent Filing)$21.62M
Total Debt (Recent Filing)$4.63M
Price to Earnings (P/E)―
Beta0.01
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.91
Shares Outstanding997,830
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-2.22
Enterprise Value/Revenue45.34
Enterprise Value/Gross Profit90.68
Enterprise Value/Ebitda0.38
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-28.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising AML Trial DataThe interim RAINIER data showing high clinical benefit, deep remissions and no cytokine release syndrome suggests mipletamig may offer a differentiated safety-efficacy profile in elderly/unfit AML. If confirmed in later trials, this durable clinical differentiation supports long-term combinability and market positioning versus current standards of care.
Extended Funding RunwayThe $60M Yorkville standby equity facility provides multi-year discretionary capital, materially reducing near-term liquidity pressure and enabling continued clinical and preclinical development. Structurally, multi-year runway supports execution of milestone-driven programs without immediate commercial revenue, improving the odds of reaching value-inflection events.
Leadership ContinuityAn internal CEO succession with the COO elevated and the prior CEO remaining as Executive Chair preserves institutional knowledge and strategic continuity during a critical clinical inflection. The promoted leader's operational and financial track record and a strengthened board reduce execution disruption risk across upcoming development and regulatory milestones.
Bears Say
Zero Revenue And Persistent LossesHaving no revenue over multiple years and persistent operating losses means Aptevo lacks commercial cash inflows to underwrite operations. This structural dependence on successful clinical outcomes or external capital increases solvency risk: failure to achieve pivotal milestones would materially worsen funding stress and strategic options.
Severe Cash BurnSustained and worsening negative operating and free cash flow, including roughly -$25.6M in 2025, demonstrates the company cannot self-fund development. This persistent cash-consumption profile heightens reliance on capital markets, risks program delays if financing tightens, and places structural pressure on resource allocation.
Material Dilution Risk From Equity FinancingApproval to issue a large share block under the standby equity agreement signals significant dilution potential if accessed. Reliance on equity lines as a primary funding mechanism can dilute existing shareholders, compress per-share economics and long-term returns, and alter investor incentives if equity issuance is used repeatedly to fund operations.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $3.95 and its highest was $1299.60 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $4.50M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on Mar 26, 2026. The company reported -$5.911 earnings per share for the quarter, beating the consensus estimate of -$5.94 by $0.029.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 997,830 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -$5.911 in its last earnings report, beating expectations of -$5.94. Following the earnings report the stock price went up 1.921%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO Stock 12 Month Forecast
Average Price Target
$21.00
▲(3342.62% Upside)
Technical Analysis
Ownership Overview
1.36% Insiders
1.27% Mutual Funds
<0.01% Other Institutional Investors
96.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---